Andrew Gordon, MD

Panelists discuss how seronegative patients may still have undetectable antibodies and respond to plasma exchange, suggesting serum factors are involved. They require different diagnostic approaches, including cell-based assays and genetic testing, to differentiate between congenital myasthenia and other disorders.

Panelists discuss how myasthenia gravis is a T-cell–dependent, B-cell–mediated autoimmune disorder affecting neuromuscular transmission through different autoantibodies (acetylcholine receptor, MuSK, and LRP4) that target the neuromuscular junction through various mechanisms including complement activation and receptor clustering disruption.